Thinking of switching your Wegovy provider? Here's what the evidence says

What NICE says about ongoing Wegovy prescribing, and why it affects your switch

NICE's recommendation for semaglutide (TA875) is specific: treatment should sit within a specialist weight management pathway that includes multidisciplinary support, and prescribers should review whether treatment is working after six months at the maintenance dose. If weight loss falls below 5%, continuing is reconsidered. That framework has a direct bearing on switching providers, because a new provider who simply re-issues a prescription without reviewing your progress isn't meeting the standard the appraisal describes.

When you transfer to a regulated online pharmacy, the receiving prescriber should look at your current dose, how long you've been on it, any side effects you've experienced, and what your weight trajectory looks like. That's not bureaucracy, it's the clinical backstop that keeps treatment safe. Wegovy's licensed indications and evidence base are worth reading before any switch, so you understand what the medicine is actually approved to do in the UK.

The NICE evidence review also notes the importance of lifestyle support running alongside pharmacological treatment. If you're comparing your options, browsing the range of Wegovy providers available in the UK can help you understand what a compliant, fully supported service actually looks like, and how far some offerings fall short of what the appraisal envisaged.

How providers actually differ: a practical comparison

Not every Wegovy provider offers the same thing. The table below sets out the features most relevant to a patient switching mid-course. None of the columns below represents a claim about any specific named competitor; they reflect the landscape our prescribers see when patients transfer in.

You can verify any UK online pharmacy at the GPhC register, a step the MHRA recommends before purchasing any prescription medicine online. Providers that supply these medicines without a valid prescription from a registered prescriber are operating outside UK law. That matters more than any price difference.

What you'll need to bring to the switch

A smooth transfer depends on two things: evidence of your current dose and a recent weight reading. Most established online pharmacies (and every legitimate one) will ask for both. At nume, dose increases also require evidence of your current treatment level before a higher pen is prescribed; that's a clinical safeguard, not a hurdle.

For patients moving from the 1.7mg or 2.4mg maintenance dose, our prescribers will review your timeline and confirm the next supply is clinically appropriate. If you've been on treatment for a while and are wondering whether Wegovy is still the right choice for your situation, the guide to choosing a Wegovy provider sets out the questions worth asking, including whether tirzepatide (Mounjaro) might be a better clinical fit.

Wegovy's higher 7.2mg dose, approved by the MHRA in April 2026 as a dedicated single-dose pen, is now part of the licensed pathway for eligible patients. Whether that applies to you is a clinical decision, not one to make from a webpage. Your prescriber is the right person to raise it with. Our clinical team handles exactly these conversations at consultation.

Once approved, your treatment ships the same working day. It arrives the next working day via DPD, tracked to your door in a plain, unbranded box, with no indication of the contents. That detail matters to a lot of people.

The cost question, and the right way to think about it

Price is often what prompts someone to look at switching. That's fair. Eli Lilly's September 2025 list-price changes pushed private Mounjaro costs higher across the board, and Wegovy pricing among private providers varies too, typically somewhere in the range of £149 to £375 per month, depending on the dose and provider, as widely reported at the time.

A lower monthly figure can mean several different things: a genuinely competitive service, a lower dose, or costs that reappear as separate prescription fees, delivery charges or consultation add-ons. It can also, in some cases, indicate a supply chain that isn't what it appears. If you're trying to find Wegovy providers near you who meet the standard for legitimate, clinically supervised treatment, proximity alone is rarely the right filter, and the MHRA has warned publicly about counterfeit weight-loss pens sold through social media and unverified websites. Sellers offering these medicines without a clinical assessment are a red flag, not a bargain. Suspected sellers can be reported via the MHRA Yellow Card scheme.

At nume, one price covers everything. We're transparent that it isn't the lowest you'll find, that's a deliberate position. For a prescription medicine, the cheapest listing answers the wrong question. The right question is whether the prescriber, the pharmacy and the supply chain are all legitimate and whether you'll get support if something changes. When you're ready, you can order Wegovy through a fully regulated pathway that includes a clinical review before every supply, or read more about how Wegovy is priced in the UK and explore all available treatment options on our treatment page.